New SRC/ABL inhibitors for chronic myeloid leukemia therapy show selectivity for T315I ABL mutant CD34+ cells

Author： Santucci Maria   Mancini Manuela   Corradi Valentina   lacobucci Ilaria   Martinelli Giovanni   Botta Maurizio   Schenone Silvia  

Publisher： Springer Publishing Company

ISSN： 0167-6997

Source： Investigational New Drugs, Vol.28, Iss.6, 2010-12, pp. : 876-878

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

New Opportunities to Treat the T315I-Bcr-Abl Mutant in Chronic Myeloid Leukaemia: Tyrosine Kinase Inhibitors and Molecules that Act by Alternative Mechanisms

By  

Current Medicinal Chemistry, Vol. 17, Iss. 13, 2010-05 ,pp. : 1220-1245

Bentham Science Publishers

Access to resources Recommend Favorite

Inhibitors of ABL and the ABL-T315I Mutation

By  

Current Topics in Medicinal Chemistry, Vol. 8, Iss. 10, 2008-07 ,pp. : 905-921

Bentham Science Publishers

Access to resources Recommend Favorite

New Bcr-Abl inhibitors in chronic myeloid leukemia: keeping resistance in check

By O'Hare Thomas   Eide Christopher A   Deininger Michael W  

Expert Opinion on Investigational Drugs, Vol. 17, Iss. 6, 2008-06 ,pp. : 865-878

Informa Healthcare

Access to resources Recommend Favorite

BCR-ABL Inhibitors in Chronic Myeloid Leukemia: Process Chemistry and Biochemical Profile

By  

Current Medicinal Chemistry, Vol. 18, Iss. 19, 2011-06 ,pp. : 2943-2959

Bentham Science Publishers

Access to resources Recommend Favorite

Nilotinib Therapy in Chronic Myelogenous Leukemia: The Strength of High Selectivity on BCR/ABL

By  

Current Drug Targets, Vol. 10, Iss. 6, 2009-06 ,pp. : 530-536

Bentham Science Publishers

Access to resources Recommend Favorite